Northwest Biotherapeutics reported $-108.65M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agenus USD -221.22M 49.89M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Celldex Therapeutics USD 456.23M 70.94M Mar/2026
Eisai JPY 898.99B 9.36B Mar/2026
Infinity Pharmaceuticals USD -37.41M 9.08M Jun/2023
Merck USD 45.88B 6.73B Mar/2026
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 90.1B 3.63B Mar/2026
Plus Therapeutics USD 11.96M 7.96M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025